We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Pulmatrix Inc (PULM) USD0.0001

Sell:$0.64 Buy:$0.69 Change: $0.026 (3.85%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Change: $0.026 (3.85%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Change: $0.026 (3.85%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Pulmatrix, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing inhaled therapies to address serious respiratory disease. The Company designs and develops inhaled therapeutic products based on its dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The Company's therapeutic candidates includes Pulmazole, for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma and in patients with cystic fibrosis (CF), PUR1800, for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and PUR3100, for the treatment of acute migraine. The Company's each of this program is enabled by its iSPERSE formulation, designed to achieve specific therapeutic objectives.

Contact details

99 Hayden Ave Ste 390
United States
+1 (781) 3572333

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$36.56 million
Shares in issue:
56.25 million
United States
US dollar

Key personnel

  • Teofilo Raad
    President, Chief Executive Officer, Director
  • Michelle Siegert
    Vice President - Finance

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.